Goodwill and Other Intangible Assets

9 Months Ended

Jan. 23, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:


(in millions)	Cardiovascular		Neuroscience		Medical Surgical		Diabetes		Total
April 25, 2025	$	8,017	$	11,716	$	19,748	$	2,255	$	41,737


Currency translation and other	20		41		94		—		155
January 23, 2026	$	8,037	$	11,757	$	19,842	$	2,256	$	41,892

No goodwill impairment was recognized during the three and nine months ended January 23, 2026 and January 24, 2025.

Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:


	January 23, 2026				April 25, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,558	$	(10,360)	$	16,550	$	(9,650)
Purchased technology and patents	11,640		(8,151)		11,600		(7,514)
Trademarks and tradenames	422		(292)		421		(283)
Other	357		(120)		355		(101)
Total	$	28,977	$	(18,923)	$	28,925	$	(17,547)
Indefinite-lived:
IPR&D	$	281	$	—	$	289	$	—

The Company did not recognize any definite-lived or indefinite-lived intangible asset impairment charges during the three and nine months ended January 23, 2026 and January 24, 2025. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three and nine months ended January 23, 2026 was $441 million and $1,364 million, respectively, including $30 million and $121 million, respectively, of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio. Intangible asset amortization expense for the three and nine months ended January 24, 2025 was $416 million and $1,243 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 23, 2026, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:


(in millions)	Amortization Expense
Remaining 2026	$	405
2027	1,608
2028	1,557
2029	1,479
2030	1,347
2031	1,268